Aurinia Pharmaceuticals Inc.

AUPH

CA05156V1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
5.03 ^USD	-1.18%		+2.44%	-44.05%

Mar. 20	ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals	CI
Mar. 07	Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing	MT

Aurinia Pharmaceuticals Inc. Reaffirms Revenue Guidance for 2021

November 03, 2021 at 06:00 am EDT

Aurinia Pharmaceuticals Inc. reaffirmed revenue guidance for 2021. The company maintains its previously stated annual revenue estimate in the range of $40 to $50 million for 2021.

Latest news about Aurinia Pharmaceuticals Inc.

ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals	Mar. 20	CI
Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing	Mar. 07	MT
Aurinia Pharmaceuticals Insider Sold Shares Worth $323,372, According to a Recent SEC Filing	Mar. 07	MT
HC Wainwright Cuts Price Target on Aurinia Pharmaceuticals to $13 From $15, Maintains Buy Rating	Feb. 22	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $8 From $13, Keeps Outperform, Speculative Risk	Feb. 16	MT
Sector Update: Health Care Stocks Higher Late Afternoon	Feb. 15	MT
Sector Update: Health Care Stocks Higher Thursday Afternoon	Feb. 15	MT
Sector Update: Health Care	Feb. 15	MT
Aurinia Pharmaceuticals Q4 Loss Widens, Revenue Increases; Concludes Strategic Review -- Shares Slump	Feb. 15	MT
Transcript : Aurinia Pharmaceuticals Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Aurinia Pharmaceuticals Inc. announces an Equity Buyback for $150 million worth of its shares.	Feb. 15	CI
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q4 Revenue $45.1M, vs. Street Est of $45.2M	Feb. 15	MT
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Fiscal Year 2024	Feb. 15	CI
AURINIA PHARMACEUTICALS FINDS NO BUYER, TO ANNOUNCE $1…	Feb. 15	RE
Kidney drug developer Aurinia fails to clinch a sale, sources say	Feb. 15	RE
Aurinia Pharmaceuticals Inc. authorizes a Buyback Plan.	Feb. 14	CI
Aurinia Pharmaceuticals Reports Higher Q4, 2023 Preliminary Revenue; Shares Rise	Jan. 05	MT
Aurinia Pharmaceuticals Provides an Update on Strategic Review	Jan. 05	CI
Aurinia Pharmaceuticals Submits Investigational New Drug Application for AUR200	Dec. 20	MT
Aurinia Pharmaceuticals Inc. Submits IND Application to US Food & Drug Administration for AUR 200	Dec. 20	CI
Aurinia Pharmaceuticals Partner Otsuka Pharmaceutical Files New Drug Application For Voclosporin in Japan	Nov. 13	MT
Aurinia Pharmaceuticals Inc. Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS for Managing Lupus Nephritis	Nov. 02	CI
Transcript : Aurinia Pharmaceuticals Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02

Chart Aurinia Pharmaceuticals Inc.

Duration

Period

More charts

Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. Its product pipeline includes AUR200 and AUR300.

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Aurinia Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.03 USD

Average target price

10.57 USD

Spread / Average Target

+110.17%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AURINIA PHARMACEUTICALS INC.	-44.05%	736M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	105B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.5B
ARGENX SE	+1.86%	22.19B
BIONTECH SE	-16.53%	21.33B
GENMAB A/S	-8.49%	18.68B
WUXI APPTEC CO., LTD.	-42.33%	16.6B
BEIGENE, LTD.	-20.09%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	14.09B
SAREPTA THERAPEUTICS, INC.	+28.85%	10.99B

Bio Therapeutic Drugs